Researchers in Belgium have succeeded in using plant seeds to
produce high yields of proteins that bear a strong resemblance to
human antibodies, thus bringing the possibility of using plant
systems as an inexpensive alternative to...
Wyeth Pharmaceuticals has announced they have entered into
collaboration with Ablynx in a deal, which aims to commercialise a
class of antibody-derived therapeutic proteins targeting diseases
that include oncology and Alzheimer's...
Nabi Biopharmaceuticals has obtained the exclusive rights to use a
plasma protein purification technology from ProMetic Life Sciences
in the large-scale development and manufacture of its hyperimmune
products, cutting production costs...
Guava Technologies aim to simplify antibody screening with its new
range of quantitative bead-based kits designed to quantify either
mouse or human IgG antibody (Immunoglobulin G) during hybridoma
Ablynx and Procter and Gamble have announced the extension of its
Nanobody drug discovery and development agreement to metabolic
targets in a move that reinforces the feeling within the industry
regarding Nanobody technology and its...
Japan's Kirin Brewery Co has bought Hematech of the US, acquiring
the latter's core technology for the production of bovine-derived
human polyclonal antibodies which could be useful in the
development of a range of human-use...
Swiss pharmaceutical firm Roche has acquired GlycArt Biotechnology
in an attempt to further strengthen Roche's capabilities in the
therapeutic antibody research sector, capitalising on their
pre-existing collaboration in September...
Merck KGaA announced its intention to relocate its pharmaceutical
research operations in Scotland to its larger biotech research
facility in the United States, withdrawing its DeImmunisation
technology service at the same time.
According to a new report the therapeutic antibody market is
expected to treble in size by 2010 as significant leaps forward
coupled with safer and more effective humanised and fully human
antibodies are pouring onto the market fulfilling...
DOR BioPharma has announced the initiation of drug design program
to identify oral, small molecule drugs to counter the effects of
botulinum toxin exposure. Currently, there are no clinically
acceptable drugs that either slow or reverse...
An antibody drug candidate to treat autoimmune diseases has been
exclusively in-licensed by KaloBios Pharmaceuticals who hope to
develop this compound into a practicable treatment for rheumatoid
arthritis (RA), which currently...
Researchers in Belgium have developed a new generation of drugs
consisting of extremely small antibodies - called nanobodies - that
can target tumour cells specifically and seem suitable for oral
Since they were introduced in the early 1990s, beta interferons
have become the standard of care for patients with the
neurodegenerative disease multiple sclerosis, but up to a third of
MS patients do not derive a benefit from these...
Applied Biosystems has introduced a system for rapidly identifying
and characterising potential antibody, diagnostic and therapeutic
candidates. The 8500 Affinity Chip Analyser can detect and measure
up to 400 antibody binding interactions...